Strategy paused Bitcoin purchases from May 18-25 to focus on repurchasing $1.5 billion of its convertible notes at an 8% discount, reducing debt from $8.2 billion to $6.7 billion. The buyback was funded by cash and equity issuance without selling any Bitcoin, which remains at 843,738 BTC valued at about $65 billion. Year-to-date, the company has gained 89,378 BTC and $6.8 billion in Bitcoin value. Executive Chairman Michael Saylor emphasized the company's strategy to balance Bitcoin accumulation with managing liabilities and dividends, targeting a 2.3% breakeven rate for Bitcoin appreciation.
Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analy...
Auditoria.AI introduced Governed Autonomy, a new framework allowing AI agents to operate within enterprise-defined policies in finance, reducing the need for human approval on every transaction. This shift addresses governance challenges in AI deploy...
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8, 2026. These events will be webcast and acce...
Rani Therapeutics Holdings, a clinical-stage biotherapeutics company, announced a registered direct offering of Class A common stock priced at-the-market under Nasdaq rules. The offering includes 12.48 million shares and pre-funded warrants for 6.21 ...
Microchip Technology has introduced new 3.3 kV HV-D3 mSiC power modules designed to enhance solid-state transformers (SSTs) for AI hyperscale data centers. These modules integrate silicon carbide MOSFETs and Schottky diodes to improve power delivery ...
